Abstract
Publication details
- DOI
- 10.18295/squmj.8.2024.050
- Journal
- Sultan Qaboos University Medical Journal, 24(3), 418-419
- Publisher
- Sultan Qaboos University
- Open access
- Gold open access
- License
- CC BY-ND 4.0
Cite this article
APA 7
Raza, H., Bhutta, M. E., & Siddique, M. H. (2025). Re: Efficacy and Safety of Vildagliptin and Remogliflozin as Add-on Therapy to Metformin in Patients of Type 2 Diabetes Mellitus. Sultan Qaboos University Medical Journal, 24(3), 418-419. https://doi.org/10.18295/squmj.8.2024.050
MLA 9
Raza, Hunain, et al. "Re: Efficacy and Safety of Vildagliptin and Remogliflozin as Add-on Therapy to Metformin in Patients of Type 2 Diabetes Mellitus." Sultan Qaboos University Medical Journal, vol. 24, no. 3, 2025, pp. 418-419. https://doi.org/10.18295/squmj.8.2024.050.
Chicago (author–date)
Raza, Hunain, Muhammad E. Bhutta, and Muhammad H. Siddique. 2025. "Re: Efficacy and Safety of Vildagliptin and Remogliflozin as Add-on Therapy to Metformin in Patients of Type 2 Diabetes Mellitus." Sultan Qaboos University Medical Journal 24 (3): 418-419. https://doi.org/10.18295/squmj.8.2024.050.
Harvard
Raza, H., Bhutta, M. E. and Siddique, M. H. (2025) 'Re: Efficacy and Safety of Vildagliptin and Remogliflozin as Add-on Therapy to Metformin in Patients of Type 2 Diabetes Mellitus', Sultan Qaboos University Medical Journal, 24(3), pp. 418-419. doi:10.18295/squmj.8.2024.050.
Vancouver
Raza H, Bhutta ME, Siddique MH. Re: Efficacy and Safety of Vildagliptin and Remogliflozin as Add-on Therapy to Metformin in Patients of Type 2 Diabetes Mellitus. Sultan Qaboos University Medical Journal. 2025;24(3):418-419. doi:10.18295/squmj.8.2024.050
IEEE
H. Raza, M. E. Bhutta, and M. H. Siddique, "Re: Efficacy and Safety of Vildagliptin and Remogliflozin as Add-on Therapy to Metformin in Patients of Type 2 Diabetes Mellitus," Sultan Qaboos University Medical Journal, vol. 24, no. 3, pp. 418-419, 2025, doi: 10.18295/squmj.8.2024.050.